JPRN-jRCT2033230017招募中Unknown
A single-center, double-blind, placebo-controlled, randomized, parallel-group study to evaluate the efficacy and safety of Intraarticular injections of autologous synovial stem cells for knee osteoarthritis (Investigator initiated clinical trial) - Autologous synovial MSC injection into the OA knee
Sekiya Ichiro0 个研究点目标入组 14 人开始时间: 2023年4月10日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Select subjects who satisfy all of the following items.
- •1) Patients whose age is 20 years or older at the time of obtaining informed consent before clinical trial.
- •2) Patients whose written informed consent has been obtained.
- •3) Patients with Kellgren-Lawrence classification grade 2 or 3 osteoarthritis of knee on X-ray examination.
- •4) Patients with mean cartilage thickness at the posterior medial femoral condyle is 0.6 mm or more as calculated by MRI scan 30 weeks prior to administration of clinical trial.
- •5) Patients with clinical symptoms of pain in the knee.
- •6) Patients in whom hyaluronic acid injections for the treatment of osteoarthritis of the knee within 10 years prior to trial registration.
- •7) Patients in whom exercise therapy for at least 3 months for osteoarthritis of the knee.
排除标准
- •Exclude any of the following.
- •[Before obtaining informed consent]
- •1) Patients with a history of surgery or arthroscopic examination in the affected knee.
- •2) Patients with a history of administration of PRP or cell injections in the affected knee.
- •3) Patients whose clinical symptoms including pain have been sufficiently improved by conservative treatments including rehabilitations in the last 3 months.
- •4) Patients who require meniscus suture or resection due to a catching sensation in the knee (symptoms of not smooth flexion and extension of the knee joint).
- •5) Patients who require meniscus suture or resection due to knee instability (Symptoms of lack of stability in the knee during daily life and exercise).
- •6) Patients with a history of obvious knee trauma, knee ligament injuries.
- •7) Patients for whom MRI is not indicated because of claustrophobia and so on.
- •8) Patients who have had any intraarticular injections (local anesthetic agent, corticosteroid agent, hyaluronic acid) or arthrocentesis in these 3 months.
- •9) Patients with active infection(including those who tested positive for infectious diseases).
- •10) Patients diagnosed or suspected as malignant tumor in these 5 years.
- •11) Patients sensitive to antibiotics (penicillin, streptomycin or amphotericin B).
- •12) Patients sensitive to animal (bovine) origin materials.
- •13) Patients with poor controlled diabetes.
- •14) Patients with an implantable cardiac device (pacemaker, defibrillator).
- •15) Patients with categorized as non-bedridden(rank A)and bedridden (rank B and C).
- •16) Patients with difficulties in self-determination because of dementia and so on.
- •17) Pregnant women, lactating women and patient who may be pregnant, or patient who desires pregnancy during clinical study.
- •18) Patient who participated in other clinical trials, patient participating in other clinical studies and patient planning to participate in other clinical studies while participating in this clinical study within 12 weeks before the start of transplantation of cellular product.
- •19) Patients for whom doctors decide as not appropriate to participate in the clinical study.
- •[At the time of the examination 15 weeks prior to the start of protocol treatment]
- •20) Patients whose reduction of cartilage thickness of the posterior medial femur of less than 0.05mm from 30 weeks to 15 weeks prior to the start of protocol treatment by MRI scan after consent obtained.
- •[At the start of protocol treatment]
- •21) Patient who participated in other clinical trials, patient participating in other clinical studies and patient planning to participate in other clinical studies while participating in this clinical study within 12 weeks before the start of transplantation of cellular product.
研究者
相似试验
已完成
不适用
A single-center, double-blind, placebo-controlled, randomized study to investigate the tolerability, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-dose ACT-541468 in healthy Japanese and Caucasian subjects.Sleeping disordersinsomniaNL-OMON45722Actelion Pharmaceuticals60
已完成
4 期
A double-blind, placebo-controlled, single-center, randomized, parallel-group clinical trial, the timing of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis.Japanese cedar pollinosisJPRN-UMIN000012861Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi150
已完成
4 期
A double-blind, placebo-controlled, single-center, randomized, parallel-group clinical trial, efficacy of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis.Japanese cedar pollinosisJPRN-UMIN000005154Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi120
进行中（未招募）
1 期
A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Ventavis®) in patients with Eisenmenger syndromePulmonary Arterial Hypertension Eisenmenger syndromeMedDRA version: 17.0Level: LLTClassification code 10037405Term: Pulmonary hypertension primarySystem Organ Class: 100000004855MedDRA version: 17.0Level: LLTClassification code 10037406Term: Pulmonary hypertension secondarySystem Organ Class: 100000004855EUCTR2014-000091-25-GBRoyal Brompton and Harefield NHS Foundation Trust15
已完成
不适用
Iloprost in patients with Eisenmenger syndromeTopic: Cardiovascular diseaseSubtopic: Cardiovascular (all Subtopics)Disease: Congenital Heart Disease and Pulmonary HypertensionCirculatory SystemISRCTN15915491Royal Brompton & Harefield NHS Trust15